The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells
Carcinoma, Non-Small-Cell Lung
About this trial
This is an interventional treatment trial for Carcinoma, Non-Small-Cell Lung focused on measuring Advanced non-small cell lung cancer, Dribbles
Eligibility Criteria
Inclusion Criteria:
- Aged 18-80 years old, pathological diagnosis of advanced non-small cell lung cancer, after treatment with radiation and chemotherapy and (or) targeted drugs disease still progress.
- Clear that heart, lung, liver, kidney at physical basic normal, and basic normal immune system function.
- No allergic reaction of biological products, asthma and other allergic constitution.
- A patient or his legal representative signed informed consent.
Exclusion Criteria:
- The obvious blood coagulation dysfunction patients.
- Patients infected with tuberculosis, hepatitis b, AIDS and syphilis positive diseases.
- Severe diabetes, high blood pressure, stroke, heart failure, and kidney disease.
- Autoimmune diseases such as systemic lupus erythematosus (sle) and Rheumatoid arthritis (ra)
- Large doses or long-term glucocorticoid, and other immunosuppressive users (more than 4 weeks).
- Pregnant and nursing women has a history of allergies of biological products.
- Collect blood and doping in another place.
- Allergies or active infection that effect the observation of Tolerance activity.
- Heart, lung, liver, kidney or bone marrow function obviously low.
- Unable or unwilling to sign a consent form or to comply with the technical requirement.
Sites / Locations
Arms of the Study
Arm 1
Experimental
DRibble vaccine
Blood samples collection: collect of 10ml patients peripheral blood, separate PBMC;Day 1: DRibble group guided by ultrasound in patients with inguinal lymph nodes injected the DRibble vaccine;Day8: collecte 50 ml peripheral blood and separate monocytes and lymphocytes;Intensify immune cells amplification;Identification of immune cell;Detection of Immune cells microbial;20-22 days: immune cells back to patients;55 days: collecte 10 ml peripheral blood, after the separation of PBMC in vitro induced to DC, cocultivate with DRibble and subcutaneous injection at 60th day;Day 75: collecte 10 ml peripheral blood, separate PBMC and detecte T cell immune response ability.